Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study

• Published in: Scientific reports Vol. 10; no. 1; p. 5964
• Main Authors: Tian, Yuxi, Reichardt, Berthold, Dunkler, Daniela, Hronsky, Milan, Winkelmayer, Wolfgang C., Bucsics, Anna, Strohmaier, Susanne, Heinze, Georg
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.04.2020; Nature Publishing Group
• Subjects: 692/4019/2776; 692/700/228; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents - therapeutic use; Antihypertensives; Austria; Cardiovascular diseases; Cohort analysis; Cohort Studies; Congestive heart failure; Databases, Factual; Demography; Diabetes; Diabetes mellitus; Diabetes Mellitus - drug therapy; Drugs, Generic - therapeutic use; Female; Generic drugs; Heart failure; Humanities and Social Sciences; Humans; Hyperlipidemia; Hyperlipidemias - drug therapy; Hypertension; Hypertension - drug therapy; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - therapeutic use; Male; Middle Aged; multidisciplinary; Population studies; Science; Science (multidisciplinary); Sensitivity analysis; Treatment Outcome; Young Adult; Austria
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-62318-y

Generic medications offer substantial potential cost savings to health systems compared to their branded counterparts. In Europe and the US, they are only approved if they are bioequivalent to the respective originator product. Nevertheless, the lack of clinical outcomes is sometimes used as the reason for hesitancy in prescribing generics. We performed an observational retrospective study on 17 branded vs. generic pharmaceutical substances for the treatment of hypertension/heart failure, hyperlipidemia, and diabetes mellitus in a dataset of 9,413,620 insured persons, representing nearly the full population of Austria, from 2007 to 2012. We compared generic vs. branded medications using hazard ratios for all-cause death and major adverse cardiac and cardiovascular events (MACCE) as outcomes of interest. Using patient demographics, health characteristics from hospitalization records, and pharmacy records as covariates, we controlled for confounding in Cox models through inverse probability of treatment weighting (IPTW) using high-dimensional propensity scores. We observed that the unadjusted hazard ratios strongly favor generic drugs for all three pooled treatment indications (hypertension/heart failure, hyperlipidemia, diabetes mellitus), but were attenuated towards unity with increasingly larger covariate sets used for confounding control. We found that after IPTW adjustment the generic formulation was associated with significantly fewer deaths in 10 of 17 investigated drugs, and with fewer MACCE in 11 of 17 investigated drugs. This result favoring generic drugs was also present in a number of sub-analyses based on gender, prior disease status, and treatment discontinuation. E-value sensitivity analyses suggested that only strong unmeasured confounding could fully explain away the observed results. In conclusion, generic medications were at least similar, and in some cases superior, to their branded counterparts regarding mortality and major cardiovascular events.